To be clear right from the start, I am a fan (and owner) of Monsanto (NYSE:MON). I think it is a fantastic (albeit flawed) company that has a major role to play in feeding the world against a backdrop of increasing pressures on land and water. I also know it's extremely controversial, and that saying anything favorable about Monsanto or the genetically enhanced seeds that it sells (alongside others like DuPont (NYSE:DD) and Syngenta (NYSE:SYT)) is a virtual guarantee for generating emails from those who want to "educate" me on how it's an evil company that will doom us all.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

Setting aside the emotional aspects of it, Monsanto is not the sterling stock idea it once was. Business is going gangbusters today, and investors have pushed up the valuation along the way. While I do believe the long-term outlook for Monsanto is excellent, investors looking to commit new money today do need to be disciplined about the price that they pay.

Fiscal Q3 Results Surprise to the Upside
Monsanto is clearly on a roll, as the company announced final results for the quarter that exceeded even its recently updated guidance. Revenue rose 17%. Corn stole the show, as revenue rose 35% on significant acreage gains for reduced refuge seeds. Soybeans were strong too (up 15%), but cotton (up 1%) and vegetables (down 10%) were both weak. Last and not least, "productivity" (herbicides, mostly) rose 14%.

Margins also improved in the quarter. Gross margin improved more than a point, with only modest improvement in seeds (10bp). While corn and soybeans both showed improved gross margin, weakness in the very lucrative cotton business hurt and vegetable seed margins (which are low to begin with) worsened. Nevertheless, operating income rose more than 30% as the company kept expense growth in R&D and SG&A at low levels. Here is one of the under-appreciated virtues of the Monsanto model - Monsanto's R&D capabilities would be beastly expensive to replicate, but the company doesn't have to increase incremental spending all that much to continue developing the pipeline.

SEE: Understanding The Income Statement

What's Next for the Bears?
The strong rebound at Monsanto over the past year or so has forced the bears to get creative to maintain their thesis. First, the idea was that Monsanto had permanently alienated farmers and was destined to lose share to DuPont and Syngenta. Then the bear story was that newer products like Genuity and Intacta weren't going to work as well as advertised or sell as well as management hoped.

Where do the bears go now? The easiest claim may be the that 2013 can't possibly be so good. The U.S. has seen some of the strongest corn planting numbers in several decades and key international markets like Brazil and Argentina are already considered "established" markets by Monsanto itself. There's also the idea out there that Monsanto and DuPont are in a "tit for tat" arms race and that DuPont will gain back share with its next releases.

Last and not least, there is the threat of government action. There are renewed pushes in the U.S. aimed at stronger (and clearer) labeling rules for foods containing ingredients grown from modified seeds.

SEE: Earning Forecasts: A Primer

Balancing Bull, Bear and Pig
Though I would not ignore DuPont or Syngenta, Monsanto seems to have a real edge when it comes to its pipeline and the recent performance of newly launched products. If DuPont, Syngenta, Dow (NYSE:DOW), BASF (OTC:BASFY) and Bayer (OTC:BAYRY) have a strong chance of beating Monsanto (and both Dow and BASF collaborate with Monsanto), it may be in beating them to newer opportunities like rice and oilseeds.

Elsewhere, while there are public perception risks to GM crops in the U.S., the reality is that there is no serious effort to ban them or even reduce their use. For good or ill, "Big Farm" will fight that battle to the death and there is just too much money (and too many votes) at stake. In fact, with the EU apparently starting to reconsider its opposition to GM crops, a large new market could open up in the years ahead - to say nothing of the potential of selling to developing regions like East Asia, South Asia, Africa and Eastern Europe.

SEE: 5 Must-Have Metrics For Value Investors

None of this is really new, though. Strong results from products like Intacta (improving soybean yield by 10% in Brazil) and strong sales numbers are good, but they'll be hard to surpass. That makes Monsanto's valuation a little tricky today. From a more technical angle, I'm content to hold Monsanto at least until the point where estimate revisions catch up to the story, and I'd love to hold this stock for many years, based on its long-term potential.

The Bottom Line
Boiling it all down for readers, I like Monsanto's business and I do think there's real momentum in the company and in the shares today. That may be fine for nimble investors, but long-term holders ought to go over the numbers carefully before jumping in now. While I believe Monsanto will reward a long-term holder, there are going to be dips along the way and it may make more sense for investors to sit tight and wait for the next one.

Disclosure - Stephen D. Simpson owns shares of Monsanto since April 2010.

Related Articles
  1. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  2. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  3. Mutual Funds & ETFs

    ETF Analysis: iShares Morningstar Small-Cap Value

    Find out about the Shares Morningstar Small-Cap Value ETF, and learn detailed information about this exchange-traded fund that focuses on small-cap equities.
  4. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  7. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  8. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  9. Mutual Funds & ETFs

    ETF Analysis: WisdomTree SmallCap Earnings

    Discover the WisdomTree Small Cap Earnings ETF, a fund with a special focus on small-cap and micro-cap stocks with positive earnings.
  10. Mutual Funds & ETFs

    ETF Analysis: iShares US Regional Banks

    Obtain information and analysis of the iShares US Regional Banks ETF for investors seeking particular exposure to regional bank stocks.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Profit Margin

    A category of ratios measuring profitability calculated as net ...
  3. Quarter - Q1, Q2, Q3, Q4

    A three-month period on a financial calendar that acts as a basis ...
  4. Debt Ratio

    A financial ratio that measures the extent of a company’s or ...
  5. Price-Earnings Ratio - P/E Ratio

    The Price-to-Earnings Ratio or P/E ratio is a ratio for valuing ...
  6. Net Present Value - NPV

    The difference between the present values of cash inflows and ...
RELATED FAQS
  1. What is the formula for calculating compound annual growth rate (CAGR) in Excel?

    The compound annual growth rate, or CAGR for short, measures the return on an investment over a certain period of time. Below ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. When does the fixed charge coverage ratio suggest that a company should stop borrowing ...

    Since the fixed charge coverage ratio indicates the number of times a company is capable of making its fixed charge payments ... Read Full Answer >>
  4. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  5. What is the difference between the return on total assets and an interest rate?

    Return on total assets (ROTA) represents one of the profitability metrics. It is calculated by taking a company's earnings ... Read Full Answer >>
  6. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!